KLKimberly Lapham

Kimberly Lapham

*This is an algorithmically generated author record based on publicly available information.

Kimberly Lapham has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AQUA-ADME: A Protein Standard Addition Framework for Absolute Quantification of Drug Metabolizing Enzymes

    by Xiaofeng Wu, Sam Zhang, R. Scott Obach, Qianying Yuan, Kimberly Lapham, Yuanyuan Shi, Lloyd Wei Tat Tang

  • Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction

    by Kimberly Lapham, Nicholas Ferguson, Mark Niosi, Theunis C. Goosen

    UGT2B4 is a highly expressed drug metabolizing enzyme in the liver contributing to the glucuronidation of several drugs. To enable quantitatively assessing UGT2B4 contribution toward metabolic clearance, a potent and selective UGT2B4 inhibitor that can be used for reaction phenotyping was sought. Initially, a canagliflozin-2´-O-glucuronyl transferase activity assay was developed in recombinant UGT2B4 and human liver microsomes (HLM) ({plus minus} 2% bovine serum albumin; BSA). Canagliflozin-2´-O-glucuronidation (C2OG) KM values in recombinant UGT2B4 and HLM were similar. C2OG formation intrinsic clearance was 5- to 7-fold higher in incubations containing 2% BSA, suggesting UGT2B4 susceptibility to the inhibitory unsaturated long-chain fatty acids released during the incubation. Monitoring for C2OG formation, 179 compounds were evaluated for UGT2B4 inhibition. Compounds that exhibited an apparent UGT2B4 IC50 of 24-fold) over the other UGT enzymes evaluated. Additionally, during this study it was discovered that the previously described UGT2B7 inhibitors 16α- and 16β-phenyllongifolol are not selective for UGT2B7. In 2% BSA, they are nearly equipotent inhibitors of UGT2B4. Clotrimazole, a potent and selective UGT2B4 inhibitor, will prove essential during UGT reaction phenotyping. Significance Statement To mechanistically evaluate drug interactions, it is essential to understand the contribution of individual enzymes to the metabolic clearance of a drug. The present study describes the development of a UGT2B4 activity assay that enabled the discovery of the highly selective and potent UGT2B4 inhibitor clotrimazole. Clotrimazole can be used in UGT reaction phenotyping studies to estimate fractional contribution of UGT2B4.


  • Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes

    by Lloyd Wei Tat Tang, Ethan DaSilva, Kimberly Lapham, R. Scott Obach

    Aldehyde oxidase (AO) is a molybdenum cofactor-containing cytosolic enzyme that has gained prominence due to its involvement in the developmental failure of several drug candidates in first-in-human trials. Unlike cytochrome P450s (P450) and glucuronosyltransferase, AO substrates have been plagued by poor in vitro to in vivo extrapolation, leading to low systemic exposures and underprediction of human dose. However, apart from measuring a drug9s AO clearance rates, it is also important to determine the relative contribution to metabolism by this enzyme (fm,AO). Although hydralazine is the most well-studied time-dependent inhibitor (TDI) of AO and is frequently employed for AO reaction phenotyping in human hepatocytes to derive fm,AO, multiple studies have expressed concerns pertaining to its utility in providing accurate estimates of fm,AO values due to its propensity to significantly inhibit P450s at the concentrations typically utilized for reaction phenotyping. In this study, we characterized icotinib, a cyclized analogue of erlotinib, as a potent TDI of AO - inactivating human liver cytosolic zoniporide 2-oxidation equipotently with erlotinib with a kinact/KI ratioof 463 and 501 min-1mM-1, respectively. Moreover, icotinib also exhibits selectivity against P450 and elicits significantly weaker inhibition against human liver microsomal UGT1A1/3 as compared to erlotinib. Finally, we evaluated icotinib as an inhibitor of AO for reaction phenotyping in cryopreserved human hepatocytes and demonstrated that it can yield more accurate prediction of fm,AO compared to hydralazine and induce sustained suppression of AO activity at higher cell densities - which will be important for reaction phenotyping endeavors of low clearance drugs. Significance Statement In this study, we characterized icotinib as a potent time-dependent inhibitor of AO with ample selectivity margins against the P450s and UGT1A1/3 and demonstrated its utility for reaction phenotyping in human hepatocytes to obtain accurate estimates of fm,AO for victim DDI risk predictions. We envisage the adoption of icotinib in place of hydralazine in AO reaction phenotyping.


  • Open Access

    In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes

    by Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma, Theunis C. Goosen

    Ertugliflozin is primarily cleared through UDP‑glucurosyltransferase (UGT)-mediated metabolism (86%) with minor oxidative clearance (12%). In vitro phenotyping involved enzyme kinetic characterization of UGTs or cytochrome P450 (CYP) enzymes catalyzing formation of the major 3-O-β-glucuronide (M5c) and minor 2-O-β-glucuronide (M5a), monohydroxy-ertugliflozin (M1 and M3), and des-ethyl ertugliflozin (M2) metabolites in human liver microsomes (HLM). Fractional clearance (fCL) estimated from HLM intrinsic clearance (CLint) indicated a major role for glucuronidation (fCL 0.96; CLint 37 µL/min/mg) versus oxidative metabolism (fCL 0.04; CLint 1.64 µL/min/mg). Substrate concentration at half-maximal velocity (Km), maximal rate of metabolism (Vmax), and intrinsic clearance (CLint) for M5c and M5a formation were 10.8 µM, 375 pmol/min/mg, 34.7 µL/min/mg and 41.7 µM, 94.9 pmol/min/mg, 2.28 µL/min/mg, respectively. Inhibition of HLM CLint with 10 µM digoxin or tranilast (UGT1A9) and 3 µM 16β-phenyllongifolol (UGT2B7/UGT2B4) resulted in fraction metabolism (fm) estimates of 0.81 and 0.19 for UGT1A9 and UGT2B7/UGT2B4, respectively. Relative activity factor scaling of recombinant enzyme kinetics provided comparable fm for UGT1A9 (0.86) and UGT2B7 (0.14). Km and Vmax for M1, M2, and M3 formation ranged 73.0 - 93.0 µM and 24.3-116 pmol/min/mg, respectively, and was inhibited by ketoconazole and montelukast (M2). In summary, ertugliflozin metabolism in HLM was primarily mediated by UGT1A9 (78%) with minor contributions from UGT2B7/UGT2B4 (18%), CYP3A4 (3.4%), CYP3A5 (0.4%), and CYP2C8 (0.16%). Considering higher ertugliflozin oxidative metabolism (fCL 0.12) obtained from human mass balance, human systemic CL is expected to be mediated by UGT1A9 (70%), UGT2B7/UGT2B4 (16%), CYP3A4 (10%), CYP3A5 (1.2%), CYP2C8 (0.5%), and renal elimination (2%). Significance Statement This manuscript describes the use of orthogonal approaches (i.e., enzyme kinetics, chemical inhibitors and recombinant enzymes) to characterize the fraction of ertugliflozin metabolism through various UGT and CYP enzyme-mediated pathways. Phenotyping approaches routinely used to characterize CYP hepatic fractional metabolism (fm) to estimate specific enzymes contributing to overall systemic CL were similarly applied for UGT-mediated metabolism. Defining the in vitro metabolic disposition and fm for ertugliflozin allows risk assessment when considering potential victim-based DDI perpetrated by co-administered drugs.


  • Open Access

    6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol

    by Kimberly Lapham, Jian Lin, Jonathan Novak, Christine Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, et al.

    6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (PF-06409577) is a direct activator of the human β1-containing adenosine monophosphate-activated protein kinase (AMPK)isoforms. The clearance mechanism of PF-06409577 in animals and humans involves uridine diphosphoglucuronosyl transferase (UGT)-mediated glucuronidation to an acyl glucuronide metabolite M1, which retains selective activation of human 1-containing AMPK isoforms. This manuscript describes a detailed characterization of the human UGT isoform(s) responsible for glucuronidation of PF-06409577 to M1. Studies using a panel of 13 human recombinant UGT (hrUGT) enzymes indicated that PF-06409577 was converted to M1 in a highly selective fashion by UGT1A1, which was further verified in human liver microsomes (HLM) treated with specific chemical inhibitors, and in different UGT1A1 expressers. Conversion of PF-06409577 to M1 by UGT1A1 occurred in a relatively selective fashion, compared to β-estradiol (ES), a conventional probe substrate of UGT1A1. KM and Vmax values describing the formation of M1 from PF-06409577 in hrUGT1A1 and microsomal preparations from human intestine, liver and kidney ranged from 131-212 μM (KM) and 107-3834 pmol/min/mg (Vmax) in the presence of 2% bovine serum albumin (BSA). Relative activity factors (RAF) were determined for UGT1A1 using PF-06409577 and ES to enable estimation of intrinsic clearance from various tissues. RAF values from PF-06409577 and ES were generally comparable with the exception of intestinal microsomes where ES over-estimated the RAF of UGT1A1 due to glucuronidation by intestinal UGT1A8 and UGT1A10. Our results suggest a potential utility of PF-06409477 as a selective probe UGT1A1 substrate for UGT reaction phenotyping and inhibition studies in preclinical discovery/development.